Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Protalix BioTherapeutics Q2 Sales $15.658M Beat $13.546M Estimate

Author: Benzinga Newsdesk | August 14, 2025 05:51am
Protalix BioTherapeutics (AMEX:PLX) reported quarterly sales of $15.658 million which beat the analyst consensus estimate of $13.546 million by 15.59 percent. This is a 16.21 percent increase over sales of $13.474 million the same period last year.

Posted In: PLX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist